Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

105Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.
Get full text

Abstract

MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre-clinical activity in chronic lymphocytic leukaemia (CLL). A phase II clinical trial was performed, starting at a dose of 85 mg/d, three times per week. Dose escalation to 110 mg or the addition of rituximab was permitted in patients without a response after two or more cycles. MGCD0103 demonstrated pre-clinical activity against CLL cells with a LC50 (concentration lethal to 50%) of 0·23 μmol/l and increased acetylation of the HDAC class I specific target histone H3. Twenty-one patients received a median of two cycles of MGCD0103 (range, 0-12). All patients had previously received fludarabine, 33% were fludarabine refractory, and 71% had del(11q22·3) or del(17p13·1). No responses according to the National Cancer Institutes 1996 criteria were observed. Three patients received 110 mg and four patients received concomitant rituximab, with no improvement in response. Grade 3-4 toxicity consisted of infections, thrombocytopenia, anaemia, diarrhoea, and fatigue. HDAC inhibition was observed in six out of nine patients on day 8. Limited activity was observed with single agent MGCD0103 in high risk patients with CLL. Future investigations in CLL should focus on broad HDAC inhibition, combination strategies, and approaches to diminish constitutional symptoms associated with this class of drugs. © 2009 Blackwell Publishing Ltd.

References Powered by Scopus

Histone deacetylases (HDACs): Characterization of the classical HDAC family

2670Citations
N/AReaders
Get full text

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment

1694Citations
N/AReaders
Get full text

Aberrant CpG-island methylation has non-random and tumour-type-specific patterns

1198Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Histone deacetylase inhibitors as anticancer drugs

933Citations
N/AReaders
Get full text

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents

605Citations
N/AReaders
Get full text

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

349Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Blum, K. A., Advani, A., Fernandez, L., Van Der Jagt, R., Brandwein, J., Kambhampati, S., … Byrd, J. C. (2009). Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. British Journal of Haematology, 147(4), 507–514. https://doi.org/10.1111/j.1365-2141.2009.07881.x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 18

62%

Researcher 6

21%

Professor / Associate Prof. 4

14%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

44%

Agricultural and Biological Sciences 8

24%

Biochemistry, Genetics and Molecular Bi... 7

21%

Pharmacology, Toxicology and Pharmaceut... 4

12%

Save time finding and organizing research with Mendeley

Sign up for free